241 related articles for article (PubMed ID: 24756803)
1. Lenalidomide.
Weisel K; Kanz L
Recent Results Cancer Res; 2014; 201():347-57. PubMed ID: 24756803
[TBL] [Abstract][Full Text] [Related]
2. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Maier SK; Hammond JM
Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Shah SR; Tran TM
Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
[TBL] [Abstract][Full Text] [Related]
4. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Palumbo A; Freeman J; Weiss L; Fenaux P
Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide: the emerging role of a novel targeted agent in malignancies.
Kalmadi S; Baz R; Mahindra A
Drugs Today (Barc); 2007 Feb; 43(2):85-95. PubMed ID: 17353946
[TBL] [Abstract][Full Text] [Related]
6. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.
Bartlett JB; Tozer A; Stirling D; Zeldis JB
Br J Cancer; 2005 Sep; 93(6):613-9. PubMed ID: 16222306
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Shortt J; Hsu AK; Johnstone RW
Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
[TBL] [Abstract][Full Text] [Related]
8. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Bonkowski J; Vermeulen LC; Kolesar JM
J Oncol Pharm Pract; 2010 Dec; 16(4):223-32. PubMed ID: 19910392
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
10. Role of lenalidomide in the treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide, a thalidomide derivative, shows promise in various applications.
Oestreicher P
ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
[No Abstract] [Full Text] [Related]
12. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
Guirguis AA; Ebert BL
Curr Opin Cell Biol; 2015 Dec; 37():61-7. PubMed ID: 26512454
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide: a synthetic compound with an evolving role in cancer management.
Saloura V; Grivas PD
Hematology; 2010 Oct; 15(5):318-31. PubMed ID: 20863427
[TBL] [Abstract][Full Text] [Related]
14. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse reactions to lenalidomide.
Imbesi S; Allegra A; Calapai G; Musolino C; Gangemi S
Allergol Immunopathol (Madr); 2015; 43(1):88-91. PubMed ID: 24998775
[TBL] [Abstract][Full Text] [Related]
16. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Vallet S; Witzens-Harig M; Jaeger D; Podar K
Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
[TBL] [Abstract][Full Text] [Related]
17. The potential of immunomodulatory drugs in the treatment of solid tumors.
Dalgleish A; Galustian C
Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830
[TBL] [Abstract][Full Text] [Related]
18. Novel lenalidomide-based combinations for treatment of multiple myeloma.
Cives M; Simone V; Brunetti O; Longo V; Silvestris F
Crit Rev Oncol Hematol; 2013 Jan; 85(1):9-20. PubMed ID: 22809697
[TBL] [Abstract][Full Text] [Related]
19. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
20. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
